The primary objective of this study is to assess the safety (by collecting adverse events and serious adverse events) of adalimumab administered every other week to patients with moderately to severly active rheumatoid arthritis who have failed prior disease-modifying anti-rheumatic drugs (DMARDs).
Study Type
EXPANDED_ACCESS
40 mg every other week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.